Statistics for Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Total visits
| views | |
|---|---|
| Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey | 2 |
Total visits per month
| views | |
|---|---|
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 2 |
| January 2025 | 0 |
| February 2025 | 0 |
File Visits
| views | |
|---|---|
| Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients Experience from anEarly Access Program in Turkey.pdf | 1 |